Ofev under the microscope: Real-World safety data for PF-ILD patients
NCT ID NCT04559581
First seen Feb 06, 2026
Summary
This completed study monitored 425 Japanese patients with progressive fibrosing interstitial lung disease (PF-ILD) who were prescribed Ofev capsules. The main goal was to track side effects, especially liver problems, in everyday medical practice. Researchers recorded any adverse drug reactions reported by doctors or the sponsor. The study excluded patients with idiopathic pulmonary fibrosis or PF-ILD due to scleroderma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASES, INTERSTITIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nintedanib (Ofev)
What this could lead to
If successful, this study could confirm that Ofev is safe and tolerable for Japanese patients with PF-ILD, supporting its continued use to slow lung damage.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove effectiveness. Side effects like liver problems remain a risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.